Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus
At the start of this year, Editas Medicine narrowed its pipeline and laid off 20% of its workforce, a move to save cash and focus on its gene-edited cell therapy candidate EDIT-301 for sickle cell disease and transfusion-dependent beta thalassemia.
Now the company has data from a handful of patients to show for it, it announced Friday.
In the company’s the Phase I/II RUBY trial, Editas reported data for the first four patients with sickle cell disease treated with EDIT-301, two of whom reached normal hemoglobin levels five months after treatment. Both patients also maintained normal hemoglobin levels at checkups 10 and six months after treatment and had a level of fetal hemoglobin greater than 40% during the same time frame.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.